Catalyst Dossier · compiled by CeliA 🧫
VYNE Therapeutics Inc. (VYNE)
Pharmaceutical Preparations · market cap $21M · as of 2026-07-18
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
18
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
VYNE Therapeutics (VYNE) is a micro-cap pharmaceutical company with a $26M market cap, 13 employees, and $24.6M in cash providing roughly 18 months of runway. The company carries a broad dermatology-focused pipeline spanning multiple Phase 2 and Phase 3 assets, though it generates negligible revenue (~$1M annually) and has burned through capital consistently, posting a $26M net loss in 2025 on $19M of R&D spend. No analyst coverage exists and no recent clinical catalysts have been disclosed.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Serlopitant High Dose | Phase 2 | Pruritus |
| 3% Minocycline Foam | Phase 2 | Acne Vulgaris |
| VPD-737 | Phase 2 | Chronic Pruritus |
| FMX101 | Phase 3 | Acne Vulgaris |
| MK0594 | Phase 2 | Urinary Incontinence |
| Topical Minocycline Foam FXFM244 | Phase 2 | Acne Vulgaris |
| FMX103 1.5% | Phase 3 | Papulopustular Rosacea |
| FMX-101, 4% minocycline foam | Phase 3 | Acne Vulgaris |
| FMX103 minocycline foam 1.5% | Phase 3 | Facial Papulopustular Rosacea |
| 5mg Serlopitant Tablets | Phase 3 | Pruritus |
| serlopitant | Phase 2 | Prurigo Nodularis |
| 5 mg Serlopitant Tablets | Phase 2 | Pruritus |
| VYN201 Gel | Phase 2 | Non-segmental Vitiligo |
| FMX114 | Phase 2 | Atopic Dermatitis |
| FMX-103 1.5% | Phase 2 | Rosacea |
| Serlopitant Tablet | Phase 2 | Epidermolysis Bullosa |
| ARK-E021 5% | Phase 2 | Acne Vulgaris |
| FDX104 (4% Doxycycline) | Phase 2 | Rash Due to Epidermal Growth Factor Receptor Inhibitors |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VYNE (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 18 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.